VASODILATORY EFFECTS OF ADENOSINE-A2 RECEPTOR AGONISTS CGS-21680 AND CGS-22492 IN HUMAN VASCULATURE

被引:32
作者
MAKUJINA, SR
SABOUNI, MH
BHATIA, S
DOUGLAS, FL
MUSTAFA, SJ
机构
[1] E CAROLINA UNIV,SCH MED,DEPT PHARMACOL,GREENVILLE,NC 27858
[2] CIBA GEIGY CORP,SUMMIT,NJ 07901
关键词
ADENOSINE RECEPTORS; CGS-21680; CGS-22492; SMOOTH MUSCLE (VASCULAR); CORONARY ARTERY (HUMAN); MAMMARY ARTERY (INTERNAL);
D O I
10.1016/0014-2999(92)90708-C
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The vasodilatory effects of the adenosine analogs, 5'-N-ethylcarboxamidoadenosine (NECA), 2-[p-(2-carboxyethyl)phenethyl-amino]-5'-N-ethylcarboxamidoadenosine (CGS 21680) and 2-[(2-cyclohexylethyl)amino]adenosine (CGS 22492) in human coronary, internal mammary artery and saphenous vein were examined in vitro. All produced concentration-dependent relaxations in arterial as well as venous rings contracted with 35 mM KCl. The concentration-response curves for NECA and CGS 21680 were parallel in the coronary. The adenosine A2 receptor antagonist, 9-chloro-2-(2-furyl)[l,2,4]triazolo[l,5-c]quinazolin-5-amine (CGS 15943A) significantly attenuated the relaxing response to the adenosine analogs in coronary artery. Although NECA and CGS 22492 were equally as effective at the highest concentration administered (both achieving = 70% relaxation at 10(-4) M) NECA (EC50 = 1.25 +/- 0.11 muM) induced greater vasodilation at lower concentrations than CGS 22492 (EC50 = 11.27 +/- 1.53 muM). CGS 21080 was the least potent of the agents tested achieving only 44% relaxation at 10(-4) M (EC50 = 4.71 +/- 0.46 muM). Coronary artery appeared to be more responsive than internal mammary artery or saphenous vein which displayed only marginal relaxation to these agents.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 25 条
  • [1] COMPARATIVE EFFECTS OF A SELECTIVE ADENOSINE A2-RECEPTOR AGONIST, CGS-21680, AND NITROPRUSSIDE IN VASCULAR SMOOTH-MUSCLE
    BALWIERCZAK, JL
    SHARIF, R
    KRULAN, CM
    FIELD, FP
    WEISS, GB
    MILLER, MJS
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 196 (02) : 117 - 123
  • [2] BELLARDINELLI L, 1983, REGULATORY FUNCTION, P378
  • [3] BRUNS RF, 1987, TOPICS PERSPECTIVES, P59
  • [4] BURNSTOCK G, 1985, METHOD PHARMACOL, V6, P193
  • [5] ADENOSINE AND SUPRAVENTRICULAR TACHYCARDIA
    CAMM, AJ
    GARRATT, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (23) : 1621 - 1629
  • [6] ADENOSINE - ELECTROPHYSIOLOGIC EFFECTS AND THERAPEUTIC USE FOR TERMINATING PAROXYSMAL SUPRA-VENTRICULAR TACHYCARDIA
    DIMARCO, JP
    SELLERS, TD
    BERNE, RM
    WEST, GA
    BELARDINELLI, L
    [J]. CIRCULATION, 1983, 68 (06) : 1254 - 1263
  • [7] THE 3 BINDING DOMAIN MODEL OF ADENOSINE RECEPTORS - MOLECULAR MODELING ASPECTS
    DOOLEY, MJ
    QUINN, RJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (02) : 211 - 216
  • [8] The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart.
    Drury, AN
    Szent-Gyorgyi, A
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1929, 68 (03): : 213 - 237
  • [9] HIGHLY SELECTIVE ADENOSINE-A2 RECEPTOR AGONISTS IN A SERIES OF N-ALKYLATED 2-AMINOADENOSINES
    FRANCIS, JE
    WEBB, RL
    GHAI, GR
    HUTCHISON, AJ
    MOSKAL, MA
    DEJESUS, R
    YOKOYAMA, R
    ROVINSKI, SL
    CONTARDO, N
    DOTSON, R
    BARCLAY, B
    STONE, GA
    JARVIS, MF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (08) : 2570 - 2579
  • [10] 2-(ARYLALKYLAMINO)ADENOSIN-5'-URONAMIDES - A NEW CLASS OF HIGHLY SELECTIVE ADENOSINE-A2 RECEPTOR LIGANDS
    HUTCHISON, AJ
    WILLIAMS, M
    DEJESUS, R
    YOKOYAMA, R
    OEI, HH
    GHAI, GR
    WEBB, RL
    ZOGANAS, HC
    STONE, GA
    JARVIS, MF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (07) : 1919 - 1924